Novel therapies for myelodysplastic syndromes

Cancer
Stefan H Faderl, H Kantarjian

Abstract

The assessment of patients with myelodysplastic syndromes (MDS) and the choice of therapies remain challenging. New therapies are now emerging after the identification of molecular targets that result in improvement of hematologic parameters and may hold promise for the prevention of disease progression. A review of the English literature was performed that included original articles and related reviews from MEDLINE (PubMed) and abstracts based on published meeting material. MDS is a heterogeneous group of disorders. Although current classification and prognostic schemes have proven valid to define subgroups, they are insufficient to take into consideration the significant biologic diversity of MDS. New molecular targets are identified as the mosaic of pathophysiologic pathways in MDS is being unraveled. Novel and targeted therapeutic agents, such as the inhibition of farnesyl transferases and receptor tyrosine kinases, more potent thalidomide analogs, and arsenic trioxide, have shown encouraging results and may offer durable benefit to patients with MDS. Although progress has been made in the understanding of clinical manifestations and some of the molecular pathways underlying ineffective hematopoiesis and leukemic transforma...Continue Reading

References

Feb 1, 1991·Current Opinion in Oncology·M R Heyman
Jul 1, 1995·Annals of Hematology·G E VerhoefM A Boogaerts
Jan 1, 1995·Leukemia & Lymphoma·C AulW Schneider
Jun 1, 1995·American Journal of Clinical Oncology·J NemunaitisR Shadduck
Apr 15, 1997·Cancer·D H BiesmaL F Verdonck
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D M Beaupre, R Kurzrock
May 26, 1999·The New England Journal of Medicine·M L Heaney, D W Golde
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M BeranH Kantarjian
Nov 30, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·N L HarrisC D Bloomfield
Mar 1, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P WijermansA Ferrant
Nov 21, 2000·Current Opinion in Oncology·D A Thomas, H M Kantarjian
Jul 6, 2001·American Journal of Industrial Medicine·A BlairK P Cantor
Nov 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockM Talpaz
Nov 13, 2001·Cancer Treatment and Research·K AllampallamA Raza
Jan 30, 2002·Acta Haematologica·D A ThomasH M Kantarjian
May 9, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C HosingI F Khouri
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lewis R SilvermanJames F Holland
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alice B KornblithJimmie C Holland
Jun 4, 2002·Nature Reviews. Genetics·Peter A Jones, Stephen B Baylin
Jul 13, 2002·Expert Review of Anticancer Therapy·Apostolia-Maria Tsimberidou, Francis J Giles

❮ Previous
Next ❯

Citations

Mar 1, 2006·Current Hematologic Malignancy Reports·Elias Jabbour, Francis J Giles
May 12, 2005·Blood Reviews·Daniel V T Catenacci, Gary J Schiller
May 3, 2005·Nature Reviews. Drug Discovery·Jean-Pierre J IssaPeter Kirkpatrick
Jun 21, 2005·Nature Reviews. Drug Discovery·Jean-Pierre Issa, Hagop Kantarjian
Mar 15, 2006·International Journal of Hematology·Shinji NakaoMasao Tomonaga
Jul 10, 2010·Drugs·Jeffrey BryanHagop Kantarjian
Aug 9, 2005·Expert Opinion on Emerging Drugs·Philip J Nivatpumin, Steven D Gore
Jan 28, 2006·Mayo Clinic Proceedings·David P Steensma, John M Bennett
May 10, 2006·British Journal of Haematology·L MannoneUNKNOWN Groupe Francais des Myelodysplasies
Aug 29, 2006·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Mary Laudon Thomas
May 23, 2006·La Revue de médecine interne·V Gelsi-Boyer, N Vey
Jul 26, 2005·Leukemia Research·J AubergerW Hilbe
Sep 10, 2009·Health and Quality of Life Outcomes·Agota SzendeAlan F List
Jun 2, 2011·Journal of Biomedicine & Biotechnology·Sebastian StintzingDaniel Neureiter
Aug 25, 2005·Clinical Journal of Oncology Nursing·Erin P Demakos, Jeanette A Linebaugh
Jun 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen D Nimer
May 3, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Norbert VeyPierre Fenaux
Aug 4, 2005·Nature Clinical Practice. Oncology·Stefan Faderl, Hagop M Kantarjian
Dec 31, 2004·Cancer Control : Journal of the Moffitt Cancer Center·Richard Stone
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Aristoteles A N GiagounidisCarlo Aul
Oct 4, 2005·Archives of Pathology & Laboratory Medicine·Ha Thanh Nishino, Chung-Che Chang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.